FDA reversed itself and gave 23andMe the green light to begin screening members for genetic risk factors for ten diseases, including Gaucher Disease, Parkinson’s and late-onset Alzheimer’s, after forcing the company to sharply curtail the scope of its consumer testing in 2013 (when their spit kits returned info on 254 genetic risk factors). It's a big win for consumer empowerment, and for enlightened, give-and-take regulation, but FDA’s concern -- that consumers, lacking the background in medicine and genetics required to interpret a finding of genetic susceptibility, would make poor medical decisions as a result -- remains valid.
From Digger the Dermatophyte to Gut Guy, grossout anthromorphications of disease are a grand tradition in pharma advertising, and Synergy's "Poop Troop" suite of poop emojis (their constipation treatment Trulance launched in January) is firmly within it.
Forget the AHCA -- a LinkedIn survey (okay, it’s a glorified web poll, but…) found that physicians are so exasperated by wrestling with insurers that 48% are ready to give a single payer system a try.
Food for thought which will soon be computer-enhanced: Elon Musk is launching an effort to develop “neural interfaces,” because he doesn’t have enough to do with Tesla and SpaceX and resistance is futile, and the founder of a neural prosthesis startup says humankind’s future will be determined through a combination of human and artificial intelligence.
Pharma product launches demand real world marketing data inputs
Real world physician and patient data inputs are transforming how pharma marketers model their audiences, m...
Telehealth and the road to point-of-care everywhere
Telehealth adoption is primed for growth as use cases broaden - what's the opportunity for healthcare brands?